NasdaqGM:VERABiotechs
Assessing Vera Therapeutics (VERA) Valuation As Price To Book And DCF Send Mixed Signals
Vera Therapeutics (VERA) has been drawing attention after a long run of clinical development work in immunological kidney and viral diseases, prompting investors to reassess the stock’s recent performance and risk profile.
See our latest analysis for Vera Therapeutics.
Vera Therapeutics’ share price has cooled recently, with a 30 day share price return showing a decline of 4.52% and a 90 day share price return showing a decline of 27.86%, even though the 1 year total shareholder return is 55%...